Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer

Exclusion Criteria

• •If any of the following criteria is met, the patient should be excluded:
• •1. Pancreatic ductal adenocarcinoma is diagnosed without histopathology / cytology;
• •2. The target lesion has received local non-drug therapy (including radiotherapy, physical and / or chemical ablation, etc.), and there is no imaging progression;
• •3. If the central nervous system metastasis is known, MRI should be performed to exclude it;
• •4. Patients with carcinoma of Vater's ampulla or adenocarcinoma of biliary tract;
• •5. Patients with partial or complete intestinal obstruction or complete biliary obstruction that cannot be relieved by active treatment;
• •6. Ascites increases gradually after 2 weeks of conservative treatment (such as diuresis, sodium restriction, excluding ascites drainage);
• •7. In the past 5 years, patients had a history of other malignant tumors, except for the following two cases: a)After other malignant tumors treated by a single operation, 5-year disease-free survival (DFS) was achieved;b)Cured basal cell carcinoma of the skin and cured carcinoma in situ of the cervix;
• •8. Pregnant or lactating women;
• •9. Active infection; Poorly controlled hypertension (≥ 150 / 100mmhg); Angina pectoris and unstable angina pectoris in recent 3 months, myocardial infarction, cardiac insufficiency (\> NYHA class II), schizophrenia, or history of psychotropic drug abuse in 1 year before enrollment;
• •10. If HBV-DNA is more than 104 copies or more than 2000 IU / ml, antiviral and liver protection therapy should be carried out first. Only when HBV-DNA is less than 104 copies (2000 IU / ml), can the patients be enrolled in the group, and continue to take antiviral drugs, monitor liver function and HBV viral load; HCV antibody or HCV-RNA were positive; HIV infected patients (non high risk group, without clinical symptoms or signs indicating HIV infection, HIV test may not be carried out);
• •11. Any of the following treatments were given within prior to enrollment:
• •1. Within 4 weeks, received surgery of grade II or above (according to the operation classification catalogue (revised version in 2014) issued by the state health and Family Planning Commission); No matter whether it is related to tumor or not);
• •2. Received extended radiotherapy within 4 weeks or limited range radiotherapy within 2 weeks (researchers in each center can judge the appropriate time to enter the group according to the recovery of toxicity after radiotherapy);
• •3. Within 4 weeks or participating in other therapeutic / interventional clinical trials;
• •4. Received local anti-tumor therapy within 4 weeks;
• •12. NCI ctcae2 or above toxicity caused by previous treatment and not yet recovered (excluding hair loss and skin pigmentation);
• •13. It is known that PD-1 monoclonal antibody and its excipients are allergic or intolerable;
• •14. There are other situations that the researchers think are not suitable for inclusion in this study.